The results are published in "Critical Care," an international journal focused on intensive care medicine.
VUNO announced that the results of a prospective study for its AI-based cardiac arrest risk management system in a journal focused on intensive care medicine.
According to a press release, the results of the study show the AI-based system’s clinical validity. The device collects and analyzes data based on respiratory rate, body temperature, blood pressure and heart rate. Using this information, it attempts to predict cardiac arrest events in patients within a 24-hour window.
The results of the study suggest that the device has a highly accurate rate of predicting these events.
In a press release, VUNO CEO Yeha Lee said, “The significance of this research lies in its successful execution of the first multicenter prospective study with many variables and challenges, thereby reaffirming the consistent predictive performance and versatility of VUNO Med®-DeepCARS™" and he said, adding "We will continue to enhance the product's credibility in clinical settings by conducting additional prospective research. We are committed to introducing it to more medical settings as essential care to ensure patient safety."
In this Q&A with Pharmaceutical Executive®, Andrew Hopkins, founder and CEO of Exscientia, reveals how artificial intelligence (AI) is currently being utilized in the pharma industry, predictions for where AI can be implemented in the future, and what pharma fears most about AI.